VENTURE PARTNER,
5AM VENTURES

Location: San Francisco Bay Area

Member Since: 2013

Membership Type: Full

June Lee, MD, is a biotechnology executive and board director with over 25 years in biotech and pharma, spanning company founding, public company operations, and board governance. She has led two companies through Chief Executive Officer (CEO) roles, executed successful fundraising, initial public offerings (IPOs), and mergers and acquisitions (M&A), and now serves on multiple public and private boards.

She currently serves on the boards of Abivax (Nasdaq/Euronext: ABVX), Eledon Pharmaceuticals (Nasdaq: ELDN), and Tenaya Therapeutics (Nasdaq: TNYA). She is also a director at Breeze Bio, a private genetic medicines company, and an advisor to Cheiron. She was founding CEO and board chair of Renasant Bio, and previously served on the board of CinCor Pharma through its IPO and acquisition by AstraZeneca for $1.8 billion.

Dr. Lee was most recently a Venture Partner at 5AM Ventures. Before that, she was founding CEO of Alumis Inc., which went public in June 2024. She previously served as Executive Vice President, Chief Development Officer, and Chief Operating Officer at MyoKardia, where she built the development organization that led to its $13.1 billion acquisition by Bristol Myers Squibb in 2020. Earlier, she was a Professor of Medicine at the University of California, San Francisco (UCSF), and led early clinical development in cardiovascular, metabolic, infectious, and respiratory disease at Genentech.

Dr. Lee is a founding board member of Elevaate Bio and previously served as Chair of the Board of Directors of the Council of Korean Americans. Dr. Lee is an Adjunct Professor at UCSF School of Medicine. She holds an undergraduate degree in chemistry from Johns Hopkins University, an MD from UC Davis, and completed clinical training in internal medicine and pulmonary & critical care medicine at UCLA and UCSF.